bioRxiv · 10.1101/2020.06.15.153387
The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection
Abstract
Many efforts to design and screen therapeutics for severe acute respiratory syndrome coronavirus (SARS-CoV-2) have focused on inhibiting viral cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on inhibiting SARS-CoV-2 entry through a hypothesized 5{beta}1 integrin-based mechanism, and indicates that inhibiting the spike protein interaction with 5{beta}1 integrin (+/- ACE2), and the interaction between 5{beta}1 integrin and ACE2 using a molecule ATN-161 represents a promising approach to treat COVID-19.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Beddingfield, B., Iwanaga, N., Zheng, W., Roy, C. J., Hu, T. Y., Kolls, J., Bix, G.. 2020-06-16. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. https://doi.org/10.1101/2020.06.15.153387
Cite the original work for its findings. Save a collection to share your selection of sources.